title: [Effect of 2 different forms of chemotherapy on remission in patients with advanced ovarian cancer].
abstract: Results of combined treatment with two different drug combinations were compared in 82 patients with advanced ovarian carcinoma (stages III-IV). 41 patients received cyclophosphamide, methotrexate, vincristine (CMV) and the other 41 patients were treated with cyclophosphamide, adriamycin and cisplatin (CAP). 34 patients (82.9%) treated with the CAP-regimen and 20 patients (48.8%) treated with CMV had remissions following treatment. The average duration of remission was longer in the CAP group (18.1 months) compared to CMV treatment (11.6 months). The mean survival time 24.3 and 14.7 months respectively. It is concluded that three drug therapy is optimal in advanced ovarian carcinoma.
authors: Frauenklinik der Medizinischen Universität.
authors: K
authors: K
authors: Krommer
authors: G
authors: G
authors: Keller
authors: I
authors: I
authors: Csaba
authors: B
authors: B
authors: Garadnay
authors: P
authors: P
authors: Göcze
mesh_terms: D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use*; D003131:Combined Modality Therapy; D003520:Cyclophosphamide / Q000008:administration & dosage; D004317:Doxorubicin / Q000008:administration & dosage; D005047:Etoposide / Q000008:administration & dosage; D005260:Female; D005500:Follow-Up Studies; D006801:Humans; D008130:Lomustine / Q000008:administration & dosage; D008727:Methotrexate / Q000008:administration & dosage; D008875:Middle Aged; D009367:Neoplasm Staging; D010051:Ovarian Neoplasms / Q000188:drug therapy* / Q000401:mortality / Q000473:pathology / Q000601:surgery; D010440:Peptichemio / Q000008:administration & dosage; D015996:Survival Rate
chemical_list: D005047:Etoposide; D008130:Lomustine; D004317:Doxorubicin; D003520:Cyclophosphamide; D010440:Peptichemio; D008727:Methotrexate
vernacular_title: Der Einfluss von zwei verschiedenen Chemotherapieformen auf die Heilungsergebnisse von Patientinnen mit fortgeschrittenem Ovarialkarzinom.